Medical Therapeutics for the Treatment of Vascular Anomalies

Ricci, Kiersten

doi:10.1016/j.coms.2023.09.013

Oral and Maxillofacial Surgery Clinics of North America

2024

DOI: 10.1016/j.coms.2023.09.013

|View full text |Cite

Medical Therapeutics for the Treatment of Vascular Anomalies

Kiersten Ricci

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Preprint1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

CDC42 Inhibitors Alter Patterns of Vessel Arborization in Skin and Tumors in vivo

Vuong,

Hachey,

Shiu

et al. 2024

Preprint

View full text Add to dashboard Cite

Tumors that arise in the epidermis must develop a vascular supply to grow beyond a millimeter in depth. Despite this dependence on angiogenesis for tumor growth, melanoma tumors are minimally responsive to anti-angiogenesis agents. Existing methods to measure changes in angiogenesis rely on two dimensional approaches that have limited ability to capture changes in the three-dimensional architecture of the tumor vascular network. Here we integrate antibody infusion, optical tissue clearing, multiphoton imaging, and three-dimensional semi-automated tracing to quantify changes in the vascular architecture of skin and tumors. Initial studies used this new vessel visualization approach to demonstrate that RhoJ knockout mice have marked differences in vessel arborization in the skin despite having similar numbers of endothelial cells. Small molecules that inhibit CDC42 GTPases, which include RhoJ, RhoQ, and CDC42, inhibit tumor growth and vessel branching within tumors to a similar degree as Braf inhibitors. In contrast to Braf inhibitors, which only affect vessel arborization in tumors, CDC42 inhibitors alter vessel arborization in normal skin, colon, and human skin organoids. Taken together, these studies identify a new class of pharmacologic agents that inhibit vessel branching in both normal skin and tumors which could have utility in treating skin cancer and skin disorders characterized by pathologic angiogenesis.

show abstract

CDC42 Inhibitors Alter Patterns of Vessel Arborization in Skin and Tumors in vivo

Vuong,

Hachey,

Shiu

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Medical Therapeutics for the Treatment of Vascular Anomalies

Cited by 1 publication

References 63 publications

CDC42 Inhibitors Alter Patterns of Vessel Arborization in Skin and Tumors in vivo

CDC42 Inhibitors Alter Patterns of Vessel Arborization in Skin and Tumors in vivo

Contact Info

Product

Resources

About